$CMND

Clearmind Medicine Inc.

Clearmind Medicine is a clinical-stage pharmaceutical company headquartered in Vancouver, British Columbia. It develops psychedelic medicines for people with health conditions including alcohol use disorder, binge drinking, obesity and metabolic disorders. Clearmind’s research focuses on MEAI, a synthetic, non-hallucinogenic molecule. Its drug candidate CMND-100 is in a Phase I/IIa clinical trial involving healthy volunteers and people with alcohol use disorder. The company is also developing an MEAI-based alcohol substitute for adult consumers. Its intellectual property portfolio includes several neuroplastogen molecules, and it holds patents related to compounds studied for therapeutic uses similar to those of MDMA.

1
1
0

No SEC Form 4 filings for $CMND in the last 30 days.

See all $CMND insider activity →
Med

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

CMND sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CMND (Clearmind Medicine Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent CMND coverage spans technology, regulation and financial news.

What's driving CMND

  • The enrollment completion reduces clinical development risk and may boost investor sentiment.

    investing.com · Nov 16, 2026

  • The recruitment milestone signals progress toward generating first patient data, which could lift the stock if results are positive.

    stocktitan.net · Oct 27, 2026

  • Wireless, connector-free charging for autonomous fleets is a product milestone that could support commercialization expectations, but it is not yet tied to revenue or contracts in the article.

    rttnews.com · Oct 12, 2026

  • The new patent strengthens CMND's IP position and may improve future valuation if the therapy advances.

    globenewswire.com · Oct 8, 2026

  • The filing may be viewed as a step toward streamlined approval, potentially lifting the stock modestly.

    rttnews.com · Oct 7, 2026

AlphAI scores every news story that mentions CMND with an AI model for sentiment and relevance, and aggregates insider trades from Clearmind Medicine Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CMND

Score
$CMNDMedAI 8/10

Clearmind completes enrollment for CMND-100 trial part C

Clearmind Medicine (CMND) completed patient enrollment for Part C of its Phase I/IIa trial for CMND-100, a treatment for neuropsychiatric and addiction disorders. The trial, conducted in the U.S. and Israel, assesses safety, tolerability, and pharmacokinetics. The company aims to develop non-hallucinogenic psychedelic-derived compounds.

Clearmind has recruited its first group of people with alcohol use disorder for a clinical trial.

Clearmind Medicine (Nasdaq: CMND) has completed patient recruitment for the first segment of Part B of its Phase I/IIa clinical trial for CMND-100, a potential treatment for alcohol use disorder (AUD). The trial, conducted at sites including Johns Hopkins and Yale, will assess safety, tolerability, and early efficacy signals in patients with moderate-to-severe AUD. According to the company, this marks a significant milestone in validating CMND-100's therapeutic potential.

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Clearmind Medicine (Nasdaq: CMND) announced a patent publication in Japan for a 3-MMC-based treatment for dyskinesia, a neurological movement disorder. The patent also covers combinations with Palmitoylethanolamide (PEA). This development is part of a collaboration with NeuroThera Labs (TSXV: NTLX). The company aims to strengthen its intellectual property portfolio in neurological disorder treatments.

Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

Related tickers